Die Mercurii, 5° Februarii 1975
Note:
American Cyanamid principles
Guidelines set out in this case to establish whether an applicant has an adequate case for the granting of an interlocutory injunction. The guidelines consider:
• Whether the claimant had a strong or merely an arguable case.
• The adequacy of damages as a remedy.
• The balance of convenience.
• Whether the status quo should be maintained.
Parliamentary
Archives,
HL/PO/JU/4/3/1262
HOUSE OF LORDS
AMERICAN CYANAMID
v.
ETHICON LIMITED
Lord Diplock
Viscount
Dilhorne
Lord
Cross of Chelsea
Lord
Salmon
Lord
Edmund-Davies
Lord Diplock
MY LORDS,
This interlocutory appeal
concerns a patent for the use as absorbable
surgical sutures of
filaments made of a particular kind of chain polymer
known as "
a polyhydroxyacetic ester " (" PHAE "). These are
sutures of
a kind that disintegrate and are absorbed by the human
body once they
have served their purpose. The Appellants ("
Cyanamid "), an American
Company, are the registered
proprietors of the patent. Its priority date
in the United Kingdom
is October 2nd, 1964. At that date the absorbable
sutures in use
were of natural origin. They were made from animal
tissues
popularly known as catgut. The Respondents (" Ethicon "), a
sub-
sidiary of another American Company, were the dominant
suppliers of
catgut sutures in the U.K. market.
Cyanamid introduced their
patented product in 1970. The chemical sub-
stance of which it is
made is a homo-polymer, i.e. all the units in the chain,
except
the first and the last (" the end stabilisers"), consist of
glycolide
radicals. Glycolide is the radical of Glycolic acid,
which is another name
for hydroxyacetic acid. By 1973 this product
had succeeded in capturing
some 15 per cent, of the U.K. market
for absorbable surgical sutures. Faced
with this competition to
catgut, Ethicon who supplied 80 per cent, of the
market were
proposing to introduce their own artificial suture (" XLG
").
The chemical substance of which it is made is not a
homopolymer but a
copolymer, i.e. although 90 per cent, by weight
of the units in the chain
consist of glycolide radicals, the
remaining 10 per cent, are lactide radicals,
which are similar in
chemical properties to glycolide radicals but not identical
in
chemical composition.
Cyanamid contend the XLG
infringes their patent, of which the principal
claim is " A
sterile article for the surgical repair or replacement of living
"
tissue, the article being readily absorbable by living tissue and
being formed
" from a polyhydroxyacetic ester." As is
disclosed in the body of the patent,
neither the substance PHAE
nor the method of making it into filaments was
new at the priority
date. Processes for manufacturing filaments from PHAE
had been the
subject of two earlier U.S. patents in 1953 (Lowe) and
1954
(Higgins). The invention claimed by Cyanamid thus consisted
of the
discovery of a new use for a known substance.
On 5th March, 1973, Cyanamid
started a quia timet action against Ethicon
for an
injunction to restrain…
Keep reading for free
Create a free CaseChat account to read American Cyanamid Co (No 1) v Ethicon Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [1975] UKHL 1
- Decision Date
CaseChat Overview and Summary
AI summary not yet generated for this case.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.